RxDoctor Payments Data

Gillian Adams, MD

Family Medicine · Bel Air, MDNPI 1912086794

Payments from drug & device makers

$1,003in general payments, 2019–2025

Across 28 payments — averaging $35.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$380
  • Novo Nordisk$139
  • Idorsia Pharmaceuticals US Inc$123
  • Otsuka America Pharmaceutical, Inc.$115
  • Merck$46
  • Lilly USA, LLC$42
  • plus $158 from 7 others

What the payments were for

  • Food & beverage$97297%
  • Education$323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,003 in reported general payments places this provider in the 65th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$58,440
Medicare patients
202
Services billed
585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$49,075
JardianceEmpagliflozin12$21,606
SynthroidLevothyroxine Sodium14$1,392
Bupropion XlBupropion Hcl17$1,337
Rosuvastatin Calcium60$1,294
Atorvastatin Calcium98$1,129
ValacyclovirValacyclovir Hcl15$937
Levothyroxine Sodium70$752
Famotidine14$498
Valsartan17$483
Amlodipine Besylate57$458
Escitalopram Oxalate20$303
Alendronate Sodium31$301
Chlorthalidone11$279
Pravastatin Sodium11$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$139$49,07535 claims
Boehringer IngelheimJardiance$27$21,60612 claims
AbbVieSynthroid$380$1,39214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →